Business
Beren attracts USD 300m in financing ahead of potential Niemann-Pick disease drug launch
Thousand Oaks, California-based Beren Therapeutics P.B.C. has secured USD 300 million in combined financing to support the potential commercial launch of...
Ethyreal launches with USD 101 million to develop dual Graves' disease and TED therapy
Cambridge, Massachusetts-based Ethyreal Bio has emerged from stealth with USD 101 million in financing to advance ETHY-001, a monoclonal antibody targeting...
Laekna takes stake in 'new co.' Vasqu Bio, hands license to PI3Kα inhibitor in USD 527m deal
Laekna (HKEX: 02105) has licensed its pre-clinical PI3Kα inhibitor LAE118 to Vasque Bio in a deal worth up to USD 527 million, positioning a...
Denmark's HERVolution to apply immunotherapy to metabolic disease under license from University of Copenhagen
HERVolution Therapeutics, a Denmark-based biotech applying immunotherapy to metabolic disease, has secured an exclusive license from the University of...
SonoThera's ultrasound-guided gene med platform gets USD 125 in Series B backing
San Francisco-based SonoThera has closed an oversubscribed USD 125 million Series B financing round to advance its ultrasound-mediated nonviral genetic...
Ideaya raises USD 300m in concurrent offering for darovasertib and DLL3 ADC pipeline
South San Francisco-based IDEAYA Biosciences (Nasdaq: IDYA) announced the pricing of an underwritten public offering of common stock and pre-funded...
Eloxx Pharma raises USD 66m in public offering to advance nonsense mutation platform
Arlington, Massachusetts-based Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX) announced the pricing of a USD 66 million public offering of common stock and...
Summit Therapeutics to raise USD 500m via public offering as ivonescimab trials progress
Miami-based Summit Therapeutics Inc. (Nasdaq: SMMT) announced a proposed underwritten public offering of common stock targeting USD 500 million in gross...
Corvus invests USD 5m in Angel Pharma for soquelitinib development in China
Corvus Pharmaceuticals (Nasdaq: CRVS) has announced a USD 5 million investment in Angel Pharmaceuticals Ltd., its China-based development partner, as part...
Parabilis raises biotech IPO bar after upsizing to USD 670m take home
Parabilis Medicines Inc (Nasdaq: PBLS), a clinical-stage company whose lead asset is the first reported direct inhibitor of the β-catenin:TCF interaction,...
SK bioscience licenses rotavirus vaccine tech from US CDC
South Korea-based SK bioscience (KRX: 302440) has licensed injectable inactivated rotavirus vaccine technology from the US Centers for Disease Control and...
XtalPi partners with undisclosed biopharma on USD 400m oral GPCR metabolic disease program
XtalPi Holdings (HKEX: 02228) has announced a partnership worth over USD 400 million with an undisclosed international biopharma company to develop oral...
Verge Labs to give AI platform boost to Tenacia's CNS programs
San Francisco-based Verge Labs has announced a platform collaboration with China-based Tenacia Biotechnology to apply its human tissue AI platform to select...
Eli Lilly adds preclinical Alzheimer's candidate through USD 1b deal with AlzeCure
Eli Lilly has agreed to license global rights to Alzstatin ACD680, a preclinical small-molecule gamma-secretase modulator for Alzheimer's disease, from...
Cartesian Therapeutics licenses mRNA CAR-T technology to WestGene Biopharma for autoimmune diseases
Cartesian Therapeutics (Nasdaq: RNAC) has licensed its mRNA payload technology to China-based WestGene Biopharma in a deal that pairs Cartesian's clinically...
The AllSci Brief
Systematic R&D and deal news. Daily.